Winduet 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination of these two agents provides complementary mechanisms of action, resulting in improved glycemic control in patients inadequately controlled by diet, exercise, or monotherapy. Winduet 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including dietary modification and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, particularly due to the sulfonylurea component. Regular monitoring of blood glucose levels, renal function, and periodic assessment of liver function tests are recommended during therapy. Dose adjustment may be necessary based on therapeutic response and tolerability. Patient education on recognizing hypoglycemia symptoms and adherence to prescribed regimen is essential for optimal outcomes.